Last updated on January 2017

A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome


Brief description of study

To demonstrate that the treatment effect in refractory nephrotic syndrome of MZR is non-inferior to that of standard therapy CTX through analyzing overall remission rate after treatment.

Clinical Study Identifier: NCT02257697

Contact Investigators or Research Sites near you

Start Over

Asahi Kasei Pharma Corporation

Renji Hospital Shanghai Jiaotong University School of Medical
Shang, China
  Connect »

Asahi Kasei Pharma Corporation

Xinhua Hospital Shanghai Jiaotong University School of Medical
Shang, China
  Connect »

Asahi Kasei Pharma Corporation

Zhongshan Hospital Fudan University
Shang, China
  Connect »